Home » Newsletters » BioWorld Science

BioWorld Science

March 19, 2021

View Archived Issues

CSPC cleared to begin clinical trials in China with SYHX-1901 for rheumatoid arthritis and SLE

MatriSys licenses MSB-3163 for acne from UCSD

Preliminary phase I/II results for SGT-001 in DMD support its further investigation

First patient enrolled in phase IIa clinical study of ARQ-252 as potential treatment for vitiligo

Exelixis collaborates with Merck KGaA and Pfizer to evaluate XL-092 plus avelumab in UC

GSK and ViiV Healthcare patent compounds for HIV infection

Kainos Medicine synthesizes new CD73 inhibitors

Kukje Pharma presents new mPGES-1 inhibitors

Peptomyc obtains approval for first-in-human phase I/II study of Omomyc

AlzeCure Pharma AB describes new compounds for AD

Dual labeling study finds no evidence of pancreatic beta cell neogenesis

Allogene Therapeutics patents CART cells for cancer

Characterization of a new mouse model of Parkinson's disease

China's NMPA approves emergency use of recombinant protein subunit vaccine against COVID-19

Phase II interim analysis data presented for apitegromab in patients with SMA

Idera reports ORR endpoint data from phase III trial of tilsotolimod for advanced melanoma

Sarepta Therapeutics presents results for SRP-9001 gene therapy in nonhuman primates

Incyte reports phase III results with ruxolitinib for COVID-19-associated ARDS

FDA approves Arcalyst for recurrent pericarditis

PGT-121 is effective without effector functions

Phase II study of AMY-101 for periodontal inflammation and gingivitis meets endpoints

New phase Ib/II trial evaluates CM-24 in advanced cancer

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 8, 2026.
New York University identifies new analogues of mannose-6-phosphate
BioWorld Science
New York University has discovered new analogues of mannose-6-phosphate reported to be potentially useful for the treatment of memory impairment,...
ASCO 2026: Chinese biopharma arrives at ASCO with pivotal wins
BioWorld
If the 2026 American Society of Clinical Oncology (ASCO) annual meeting in Chicago from May 30 to June 3 demonstrated anything about the evolution of China’s...
Bial-Portela discovers new OX1 receptor antagonists
BioWorld Science
Bial-Portela & Ca SA has patented new orexin OX1 receptor antagonists potentially useful for the treatment of anxiety disorders, depression, eating disorders,...
Autobahn on the fast track with bipolar thyroid agonist
BioWorld
Achieving high marks in the phase II Amplify-BD trial for bipolar I and II depression, Autobahn Therapeutics Inc.’s elunetirom, a brain-penetrant central nervous...